# A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT00531817** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 619 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** Placebo
- **DRUG:** Permitted DMARDs

## Key facts

- **NCT ID:** NCT00531817
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-06
- **Final completion:** 2011-03
- **Target enrollment:** 619 (ACTUAL)
- **Last updated:** 2012-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531817, "A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00531817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*